R Is Acyclic Patents (Class 514/625)
  • Patent number: 11944604
    Abstract: A spirooxindole nanoformulation includes a proniosome loaded with a spirooxindole derivative.
    Type: Grant
    Filed: March 10, 2023
    Date of Patent: April 2, 2024
    Inventors: Assem Barakat, Fardous F. El-Senduny, Mohammad Shahidul Islam, Abdullah Mohammed Al Majid, Yaseen Ali Mosa Mohamed Elshaier, Eman Ahmed Ibrahim Mazyed, Farid A. Badria
  • Patent number: 11918659
    Abstract: Described herein are materials and methods for inducing therapeutic hypothermia in a subject in need thereof.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: March 5, 2024
    Inventors: Sylvia Daunert, Suzana Hamdan, Dalton Dietrich, Sapna Deo, Helen Bramlett
  • Patent number: 11921120
    Abstract: This invention provides reagents, methods and biochemical markers for identifying and providing therapeutic intervention for individuals with metabolic dysfunction, or individuals at risk for metabolic dysfunction.
    Type: Grant
    Filed: March 14, 2021
    Date of Patent: March 5, 2024
    Assignee: Duke University
    Inventors: John F. Rawls, James E. N. Minchin
  • Patent number: 11730687
    Abstract: Provided are an emulsion structure for enhancing skin absorption and a method of preparing the same. According to a composition of an aspect of the present disclosure, due to a hexagonal structure that can mimic intercellular lipid ingredients of skin, the composition has excellent formulation safety and piezoelectric properties capable of generating a microcurrent, and accordingly, the composition is able to enhance skin absorption of a physiologically active substance without damaging the skin barrier.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: August 22, 2023
    Assignee: COSMAX, INC.
    Inventors: Min Joo Noh, Jun Bae Lee, Myeong Sam Park
  • Patent number: 11717473
    Abstract: A skin cleansing agent containing the following components (A), (B), and (C): a particle (A) including (A1), (A2), and (A3), (A1) a water-holding oil agent in an amount of from 0.0001 to 13 mass % in the skin cleansing agent, (A2) a moisturizing agent in an amount of from 0.001 to 25 mass % in the skin cleansing agent, and (A3) a polymer; a surfactant (B); and water (C).
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: August 8, 2023
    Inventors: Shiho Fukai, Kaori Umehara, Toshiaki Ozawa
  • Patent number: 11555021
    Abstract: This disclosure concerns fatty acid derivatives, pharmaceutical compositions comprising the fatty acid derivatives, and methods of using the fatty acid derivatives, for example, to treat inflammation, chronic itch, chronic pain, an autoimmune disorder, atherosclerosis, a skin disorder, arthritis, a neurodegenerative disorder, or a psychiatric disorder in a subject. In some embodiments, the fatty acid derivative is a compound, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, having a structure according to: wherein X is from 1-16 carbons in length, Z is aliphatic from 1-16 carbons in length, or is not present, Y is selected from: R1, R2, and R3 are independently hydrogen or lower alkyl, R4 is lower alkyl, hydroxyl, carboxyl, or amine, R5 is hydrogen, lower alkyl, or halide, R6 is hydroxyl or substituted thiol, and each R7 is independently hydrogen or fluoride or is not present and the adjacent carbons form alkyne.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: January 17, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christopher Ramsden, Gregory Keyes
  • Patent number: 11478489
    Abstract: The disclosure relates to the treatment of primary and metastatic cancer using radiation. Specifically, the disclosure relates to methods providing for the selective accretion of cytoprotective agent in tissues and/or organs, sensitive to radiation that are adjacent to malignant tumors prior to radiation of the tumors at a dose that otherwise would be toxic to the tissues and/or organs, but are necessary to achieve ablative outcome on the tumors.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: October 25, 2022
    Inventors: James Tour, Cullen Taniguchi, Kathy Mason
  • Patent number: 11351131
    Abstract: An anti-inflammatory composition is disclosed. The anti-inflammatory composition is useful for a pharmaceutical composition or a cosmetic composition by not only having excellent stability on the skin and therefore being harmless to the human body, but also by controlling the expression of an inflammatory skin disease-related mediating factor and thereby exhibiting an excellent anti-inflammatory effect.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 7, 2022
    Assignee: NEOPHARM CO., LTD.
    Inventors: Ji Yeon Park, Minhee Kim, Bu-Mahn Park, Kyung Sook Yoo, Sung Woo Kim, Hye Seong Shin
  • Patent number: 11213569
    Abstract: Topical formulations containing erythropoietin (EPO), and also preferably fibronectin (FN), especially gel formulations, are used to accelerate wound healing, e.g., from a burn, compared to the healing process without such a formulation being applied. Methods of preparing the formulations are also provided.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: January 4, 2022
    Assignee: Remedor Biomed Ltd.
    Inventor: Saher Hamed
  • Patent number: 10905147
    Abstract: The present invention relates to a process for preparing an additive as a food supplement based on algae for birds and animals. It also describes the food additive obtained, formulated with seaweed extract, whey, malto-dextrin, proteins, amino acids, minerals, fiber, fat, hormones, and has a final powder form. In addition, the use of the food additive to increase the weight gain in animals, the weight gain in eggs of birds, and for the production of meat in birds and animals is described.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: February 2, 2021
    Inventor: Marcelo Brintrup Meeder
  • Patent number: 10813893
    Abstract: The present invention has shown that not all salts of pyruvic acid enhance lung functions or enhance the synthesis of lung surfactants and that certain salts of pyruvic acid with the correct concentrations of calcium, phosphate and magnesium, are synergistic in their ability to enhance the synthesis of lung surfactants that will enhance lung alveoli functions, while decreasing coughing and lung tightness, and increasing oxygen saturation values to prevent hypoxemia. This patent demonstrates that the sodium pyruvate formula with calcium, phosphate and magnesium was superior over standard sodium pyruvate formula in saline alone in the removal of mucus, reduction of lung or sinus infections, and in reducing drug side effects and congestion.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: October 27, 2020
    Inventor: Alain Martin
  • Patent number: 10688065
    Abstract: Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 23, 2020
    Assignee: Harbins Ruhr Bioscience, Inc.
    Inventors: Erich Gulbins, Karl Sebastian Lang, Judith Bezgovsek
  • Patent number: 10632591
    Abstract: A polishing pad for polishing a surface, material for a polishing pad and a method for manufacturing material for a polishing pad. A polishing pad has a backing layer and a polishing layer made of sheep wool fibres fixed onto a surface of the backing layer, wherein the polishing layer has loops made of sheep wool fibres.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: April 28, 2020
    Assignee: KWH MIRKA LTD
    Inventors: Hans Hede, Göran Höglund
  • Patent number: 10441555
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methyl sulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: October 15, 2019
    Assignee: Olatec Therapeutics LLC
    Inventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse
  • Patent number: 10016377
    Abstract: The present invention relates to method of treatment of hepatitis C using bufexamac or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering bufexamac or a derivative thereof in combination with one or more anti-hepatitis C drugs.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: July 10, 2018
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi
  • Patent number: 9661847
    Abstract: A personal product antimicrobial preservative composition for preservation of topical personal care formulations is provided and includes [A] one or more undecylenic acid derivatives depicted by Formula (I), [B] one or more octanoic acid derivatives depicted by Formula (II), and [C] 2-phenoxy ethanol or 2-ethyl hexyl glyceryl ether or mixture of these two ‘liquid alcohol ethers’; wherein, each of the two components [A] and [B] is present in the range of 5 to 20% by weight and together [A] and [B] constitute 10 to 30% by weight and the ‘liquid alcohol ether’, component [C], is present 70 to 90% by weight of the total preservative composition. A method for preserving personal care product from microbial attack is provided containing an aqueous phase comprising three component composition from about 0.5 to 2.5% by weight of the total personal care formulation.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: May 30, 2017
    Assignee: Galaxy Surfactants Ltd.
    Inventors: Nirmal Koshti, Shraddha Kiran Ratnaparkhe, Devyani Ashok Mali, Bhagyesh Sawant, Pooja Dinkar Vaidya
  • Patent number: 9439880
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: September 13, 2016
    Inventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Breese
  • Patent number: 9216162
    Abstract: Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: December 22, 2015
    Inventor: Glenn A. Goldstein
  • Patent number: 9205067
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: December 8, 2015
    Inventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse
  • Patent number: 9168318
    Abstract: Provided is an oxidative reduction potential (ORP) water solution that is stable for at least twenty-four hours and methods of using the solution. The present invention provides a method of preventing or treating a condition in a patient, which method comprises administering a therapeutically effective amount of the ORP water solution. Additionally provided is a method of treating impaired or damaged tissue, which method comprises contacting the tissue with a therapeutically effective amount of the ORP water solution. Further provided is a method of disinfecting a surface, which method comprises contacting the surface with an anti-infective amount of the ORP water solution.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: October 27, 2015
    Assignee: Oculus Innovative Sciences, Inc.
    Inventor: Hojabr Alimi
  • Publication number: 20150133560
    Abstract: The invention relates to a surfactant concentrate which contains at least one anionic surfactant, an N-methyl-N-acylglucamine, a solvent and optionally one or more additives. The invention also relates to a method for producing the surfactant concentrate. The invention further relates to a method for producing cosmetic, dermatological or pharmaceutical compositions.
    Type: Application
    Filed: May 29, 2013
    Publication date: May 14, 2015
    Applicant: Clariant Finance (BVI) Limited
    Inventors: Peter Klug, Carina Mildner
  • Patent number: 9029293
    Abstract: An inhibitor for tobacco axillary bud growth, the inhibitor containing one or more cell division inhibitors selected from pyridine-based compounds and benzamide-based compounds. This inhibitor may further include an aliphatic alcohol having 6 to 20 carbon atoms in combination with the one or more cell division inhibitors.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: May 12, 2015
    Assignee: SDS Biotech K.K.
    Inventors: Motoki Tanaka, Keijitsu Tanaka, Takeshi Shibuya, Eiji Ikuta, Kotaro Yoshinaga, Yuki Yamaguchi
  • Publication number: 20150118173
    Abstract: The invention relates to a formulation comprising caprylic acid ethanolamide and/or capric acid ethanolamide in combination with an aluminium salt and to its use.
    Type: Application
    Filed: March 28, 2013
    Publication date: April 30, 2015
    Inventors: Mike Farwick, Oliver Springer, Matthias Mentel, Stefan Bergfried
  • Publication number: 20150094373
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 2, 2015
    Inventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse
  • Patent number: 8981148
    Abstract: An esteramide compound of the following formula (I): R1OOC-A-CONR2R3??(I) is described, wherein: A is a covalent bond or a methylene group —CH2—; R1 is an optionally substituted, saturated or unsaturated aliphatic or cycloaliphatic hydrocarbon group including from 5 to 36 carbon atoms, R2 and R3, either identical or different, are groups selected from a hydrogen atom, and optionally substituted hydrocarbon groups, preferably including from 1 to 36 carbon atoms, and R2 and R3 not being simultaneously hydrogen atoms. Also described, are applications for using the esteramide compound, notably as a solvent.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: March 17, 2015
    Assignee: Rhodia Operations
    Inventors: Massimo Guglieri, Thierry Vidal
  • Patent number: 8974817
    Abstract: Disclosed is a novel transdermally absorbable preparation which enables the efficient, stable and long-term administration of a drug to a living body. More specifically, the transdermally absorbable preparation comprises: a laminate comprising an outer film, a drug-containing layer and a support layer laminated in this order from the side to be contacted with the skin; and a fixing means for fixing the laminate on the skin. In the transdermally absorbable preparation, the outer film is a drug-permeable polymer film that can control the release of the drug into the skin and is provided as a surface of the laminate which is to be contact with the skin.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: March 10, 2015
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventors: Takeshi Ito, Miho Ishigure
  • Publication number: 20150065576
    Abstract: A therapy for renal diseases, in particular renal diseases, which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, palmitoylethanolamide and diethanolamide of fumaric acid are used in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Francesco Della Valle, Raffaele Migliaccio, Maria Federica Della Valle
  • Patent number: 8945603
    Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: February 3, 2015
    Assignee: Boston Foundation for Sight
    Inventor: Perry Rosenthal
  • Patent number: 8937100
    Abstract: Cosmetic compositions comprising calcium citrate and at least one N-acylated aminoalcohol according to formula (I). Provided is a method of treating aged skin, comprising topically applying to the aged skin a composition comprising a compound of Formula (I) in an amount effective to provide an anti-ageing effect. The compound of Formula (I) is used to prevent skin and/or to help to maintain or improve moisture retention and/or to fight against the signs of skin ageing. The N-acylated aminoalcohol of formula (I) acts as a ceramidase inhibitor. The combination of at least one compound of formula (I) and calcium citrate stimulates keratinocyte differentiation.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: January 20, 2015
    Assignee: Cognis IP Management GmbH
    Inventors: Philippe Moussou, Olga Freis, Louis Danoux, Philippe Grisoni, Laurent Bailly
  • Patent number: 8933119
    Abstract: A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: January 13, 2015
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Publication number: 20150010496
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 8, 2015
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam Cox
  • Publication number: 20150010636
    Abstract: A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range up to seven days. Tests conducted on laboratory rats established that the method reduced the incidence of adhesions from 100 percent (100%) in a test model to near zero in the majority of treated animals. In an alternative embodiment, andrographalide was delivered via a pump with similar results. In still another embodiment, an effective amount of 50% phosphatidylchorene and propylene glycol was delivered, via a pump, into the abdominal cavity, again with similar results.
    Type: Application
    Filed: September 10, 2014
    Publication date: January 8, 2015
    Applicant: ANHESE LLC
    Inventor: John P. Delaney
  • Patent number: 8927607
    Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: January 6, 2015
    Assignee: Hikma Pharmaceuticals LLC
    Inventor: Murray Ducharme
  • Patent number: 8927608
    Abstract: A formulation comprising dexamphetamine and lys-dexamphetamine useful in the treatment of ADHD or fatigue.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier
  • Publication number: 20140377291
    Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.
    Type: Application
    Filed: February 7, 2013
    Publication date: December 25, 2014
    Inventors: Michael A. Fischbach, Jeffrey A. Bluestone, Cristina Penaranda, Laura Brown, Jon Clardy
  • Publication number: 20140363395
    Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.
    Type: Application
    Filed: July 24, 2014
    Publication date: December 11, 2014
    Inventors: Theodore J. Nitz, Janet A. Gaboury, Christopher J. Burns, Sylvie Laquerre, Daniel C. Pevear, Thomas A. Lessen, David J. Rys
  • Publication number: 20140363475
    Abstract: An oil-in-water emulsion skin cosmetic composition comprising the following components (A), (B), (C), (D) and (E): (A) from 1 to 10% by mass of an oil agent which is liquid at 25° C., (B) from 1 to 6% by mass of an oil agent which is solid or semi-solid at 25° C., (C) from 0.7 to 3.5% by mass of linear alcohol having 12 to 22 carbon atoms, (D) from 0.2 to 1% by mass of at least one selected from the group consisting of an ionic surfactant and a nonionic surfactant having an HLB of 12.5 to 15, and (E) water, wherein the mass ratio of the component (B) to the component (A), (B)/(A), is from 0.3 to 1.0, and emulsion particles have a number-average particle diameter of 1.0 to 3.0 ?m.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Applicant: KAO CORPORATION
    Inventors: Takashi TANISHIMA, Aki YUYAMA, Shinichi TSUKII
  • Patent number: 8906966
    Abstract: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: December 9, 2014
    Inventors: Paul Sherwood, David Keith Davies
  • Publication number: 20140335150
    Abstract: The invention relates to a topical patch comprising a therapeutic compound-impermeable backing layer, a self-adhesive matrix based on polysiloxanes and containing capsaicin or a therapeutic compound analogous to capsaicin, and a protective film to be removed before use, in which the matrix contains liquid microreservoirs based on an amphiphilic solvent, in which the therapeutic compound is present in completely dissolved form and the concentration of the therapeutic compound in the microreservoir droplets is below the saturation concentration. The invention furthermore relates to a process for its production and its use in the treatment of neuropathic pain.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Inventor: Walter Muller
  • Patent number: 8883131
    Abstract: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion: 1600-2400 IU/mL Vitamin A Palmitate, 0.64%-0.96% Thiamine Hydrochloride, 0.64%-0.96% Pyridoxine Hydrochloride, 4.8%-7.2% Niacinamide, 2.85%-5.2% D-Panthenol, 1.6%-2.4% L-Arginine, 3.6%-4.4% Methyl Sulphonyl Methane (MSM), 0.08%-0.12% Ginger Oil, 0.08%-0.12% Cinnamon Oil, 0.0996%-0.1494% Oleoresin Capsicum, 1.3%-1.95% Magnesium, 2.4%-3.6% Zinc, 0.192%-0.288% Manganese, 2.6%-3.9% Urea, 2.4%-3.6% Sodium Glycerophosphate, 4.8%-7.2% L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: November 11, 2014
    Inventors: Robert Peter Taylor, Kartar Singh Lalvani, Ajit Lalvani
  • Publication number: 20140323420
    Abstract: Described herein are compositions and methods for treating or preventing a sexually transmitted infection in a subject
    Type: Application
    Filed: November 8, 2012
    Publication date: October 30, 2014
    Inventors: Stephen Dewhurst, David Easterhoff, Brad Nilsson, John Dimaio, Alan Smrcka, Jerry Yang, Christina Capule
  • Publication number: 20140296294
    Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Xiang-qun XIE, Peng YANG, Rentian FENG
  • Publication number: 20140286949
    Abstract: The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.
    Type: Application
    Filed: October 25, 2013
    Publication date: September 25, 2014
    Applicant: Dana-Farber Cancer Institute
    Inventors: S. Brian Wilson, Glenn Dranoff, Silke Gillessen
  • Publication number: 20140275053
    Abstract: The present invention provides a composition for controlling plant diseases having an excellent control efficacy on plant diseases. A composition for controlling plant diseases comprising an amide compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof and at least one kind of compounds selected from the group (A) consisting of kresoxim-methyl, azoxystrobin, pyraclostrobin, picoxystrobin, enestrobin, trifloxystrobin, dimoxystrobin, fluoxastrobin, orysastrobin, famoxadone, fenamidone, metominostrobin, a compound represented by a formula (II) and pyribencarb: shows an excellent controlling efficacy on plant diseases.
    Type: Application
    Filed: October 26, 2012
    Publication date: September 18, 2014
    Inventors: Atsushi Iwata, Makoto Kurahashi
  • Publication number: 20140271596
    Abstract: The present invention relates to an emulsified hydrogel composition and to a production method therefor, wherein, by incorporating between 20 and 30 percent by weight of a gelling solution and an emulsion obtained by mixing between 45 and 60 percent by weight of an aqueous component and between 15 and 30 percent by weight of an oil component, it is possible to simultaneously provide the skin with an aqueous fraction and an oil fraction, and it is possible to enhance functionality due to the inclusion of a high content of a dermatologically active component dissolved in the oil component.
    Type: Application
    Filed: September 12, 2012
    Publication date: September 18, 2014
    Applicant: GENIC CO., LTD.
    Inventors: Sung Jang Kim, Hyong-ii Park, Jae Han Cho, Eun Kyoung Choi, Jae hoon Kwak, Jae Min Lim, Hyun Jun Lim, Jai Hyun Kim, Min Seok Kim, Jin A. Yang, Hyun Oh Yoo, Jong Chul Kim
  • Patent number: 8809390
    Abstract: Disclosed is a compound having an acceleration effect on the secretion of human ?-defensin, LL-37, which is a human-derived anti-microbial peptide, a method for preparing same, and a composition for accelerating the secretion of anti-microbial peptide having same as an active ingredient, and the compound and the composition using same of the present invention enhance the anti-microbial effect and the immunity control effect that the anti-microbial peptide has in the body by accelerating the secretion of the anti-microbial peptide in the body.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: August 19, 2014
    Assignee: Neopharm Co., Ltd.
    Inventors: Byoeung-Deog Park, Jong-Hwan Bae, Se-Kyoo Jeong, Hyoung-Sub Gwak
  • Publication number: 20140220139
    Abstract: The present invention provides a ceramide lamella structure comprising a glucoside surfactant, a preparation method thereof, and a skin composition for external use containing the same. According to the skin preparation composition for external use of the present invention, phase stability is very excellent and a greater amount of ceramides can be stably formed according to the stability of ceramides using multilayered lamellar liquid crystals, thereby showing excellent skin moisturizing and skin barrier function repairing effects when applied to the skin.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 7, 2014
    Inventors: Seung Han Park, Byung Guen Chae, Sang Hoon Han
  • Publication number: 20140199265
    Abstract: The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.
    Type: Application
    Filed: January 11, 2013
    Publication date: July 17, 2014
    Applicant: Mead Johnson Nutrition Company
    Inventors: Chenzhong Kuang, Yan Xiao, Eduard Poels, Zeina Jouni, Dirk Hondmann
  • Patent number: 8779003
    Abstract: Disclosed herein is a method for prolonging analgesic effect of a membrane permeable local anesthetic in a subject in need thereof. The method uses cinnamaldehyde as an adjuvant which, when administered prior to or simultaneously with the administration of a local anesthetic, prolongs the analgesic effect of the local anesthetic. Also disclosed herein is a method for providing analgesic effect in a subject in need thereof. The method uses cinnamaldehyde as an analgesic compound which, when administered alone to the subject in an analgesically effective amount, provides the analgesic effect.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: July 15, 2014
    Assignee: Mackay Memorial Hospital
    Inventor: Yu-Chun Hung
  • Publication number: 20140194522
    Abstract: Provided is an emulsion composition comprising the following ingredients (A), (B), (C), (D), (E), and (F): (A) glyceryl monofatty acid ester derived from a linear-chain fatty acid having 10 to 24 carbon atoms; (B) a higher alcohol having 10 to 24 carbon atoms; (C) a ceramide; (D) an anionic surfactant; (E) a polar oil selected from branched fatty acid esters having an IOB of from 0.2 to 0.85 and having a hydroxyl group or an amino group; and (F) water, wherein the mass ratio of the total content of ingredients (A), (B), and (C) and ingredient (D) in terms of acid to the content of ingredient (E), ((A)+(B)+(C)+(D))/(E), is from 1.2 to 25.
    Type: Application
    Filed: August 8, 2012
    Publication date: July 10, 2014
    Applicant: Kao Corporation
    Inventors: Kazuhiro Kaizu, Koji Yokoyama